Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated:  2/27/2017
Children's Hospital of Michigan
mi
from
Detroit, MI
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated: 2/27/2017
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated:  2/27/2017
Montefiore Medical Center
mi
from
Bronx, NY
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated: 2/27/2017
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated:  2/27/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated: 2/27/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated:  2/27/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated: 2/27/2017
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated:  2/27/2017
Baylor College of Medicine/Texas Children's Hospital
mi
from
Houston, TX
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders
Status: Enrolling
Updated: 2/27/2017
Baylor College of Medicine/Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated:  2/27/2017
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated: 2/27/2017
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated:  2/27/2017
UCSD
mi
from
San Diego, CA
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated: 2/27/2017
UCSD
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated:  2/27/2017
University of Miami School of Medicine
mi
from
Miami, FL
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
Status: Enrolling
Updated: 2/27/2017
University of Miami School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
Childrens National Medical Center
mi
from
Washington,
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
Children's Diagnostic and Treatment Center
mi
from
Ft. Lauderdale, FL
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
Children's Diagnostic and Treatment Center
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
University of Miami / Jackson Memorial Medical Center
mi
from
Miami, FL
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
University of Miami / Jackson Memorial Medical Center
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
Cook County Children's Hospital
mi
from
Chicago, IL
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
Cook County Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
Tulane Medical Center
mi
from
New Orleans, LA
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
Tulane Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
University of Maryland
mi
from
Baltimore, MD
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
Children's Hospital at Montefiore Medical Center
mi
from
Bronx, NY
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
Children's Hospital at Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
Mount Sinai Hospital
mi
from
New York, NY
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated:  2/27/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status: Enrolling
Updated: 2/27/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females
PROJECT ÒRÉ: An Innovative Friendship Based HIV/STI Intervention for High Risk African American Females
Status: Enrolling
Updated:  2/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females
PROJECT ÒRÉ: An Innovative Friendship Based HIV/STI Intervention for High Risk African American Females
Status: Enrolling
Updated: 2/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
University of California at San Francisco
mi
from
San Franciso, CA
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
University of California at San Francisco
mi
from
San Franciso, CA
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Children's Hospital National Medical Center
mi
from
Washington,
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Children's Hospital National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
University of Southern Florida College of Medicine
mi
from
Tampa, FL
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
University of Southern Florida College of Medicine
mi
from
Tampa, FL
Click here to add this to my saved trials
Immunologic Memory (Supp. of ATN 024)
Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Immunologic Memory (Supp. of ATN 024)
Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Immunologic Memory (Supp. of ATN 024)
Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
University of California at San Francisco
mi
from
San Franciso, CA
Immunologic Memory (Supp. of ATN 024)
Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
University of California at San Francisco
mi
from
San Franciso, CA
Click here to add this to my saved trials
Immunologic Memory (Supp. of ATN 024)
Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Children's Hosp Natinal Med Center
mi
from
Washington,
Immunologic Memory (Supp. of ATN 024)
Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Children's Hosp Natinal Med Center
mi
from
Washington,
Click here to add this to my saved trials
Immunologic Memory (Supp. of ATN 024)
Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Tulane Medical Center
mi
from
New Orleans, LA
Immunologic Memory (Supp. of ATN 024)
Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Tulane Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers
Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers Part A: Focus Group And Measurement Evaluation
Status: Enrolling
Updated:  2/27/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers
Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers Part A: Focus Group And Measurement Evaluation
Status: Enrolling
Updated: 2/27/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Intervention Development for Newly Diagnosed Youth With HIV
Intervention Development for Newly Diagnosed Youth With HIV
Status: Enrolling
Updated:  2/27/2017
Stroger Hospital of Cook County
mi
from
Chicago, IL
Intervention Development for Newly Diagnosed Youth With HIV
Intervention Development for Newly Diagnosed Youth With HIV
Status: Enrolling
Updated: 2/27/2017
Stroger Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Intervention Development for Newly Diagnosed Youth With HIV
Intervention Development for Newly Diagnosed Youth With HIV
Status: Enrolling
Updated:  2/27/2017
Montefiore Medical Center
mi
from
New York, NY
Intervention Development for Newly Diagnosed Youth With HIV
Intervention Development for Newly Diagnosed Youth With HIV
Status: Enrolling
Updated: 2/27/2017
Montefiore Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Intervention Development for Newly Diagnosed Youth With HIV
Intervention Development for Newly Diagnosed Youth With HIV
Status: Enrolling
Updated:  2/27/2017
University of Puerto Rico, School of Medicine
mi
from
San Juan,
Intervention Development for Newly Diagnosed Youth With HIV
Intervention Development for Newly Diagnosed Youth With HIV
Status: Enrolling
Updated: 2/27/2017
University of Puerto Rico, School of Medicine
mi
from
San Juan,
Click here to add this to my saved trials
PTSD and Risk Behavior in HIV Positive Female Adolescents
PTSD and Risk Behavior in HIV Positive Female Adolescents
Status: Enrolling
Updated:  2/27/2017
University of Miami
mi
from
Miami, FL
PTSD and Risk Behavior in HIV Positive Female Adolescents
PTSD and Risk Behavior in HIV Positive Female Adolescents
Status: Enrolling
Updated: 2/27/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
PTSD and Risk Behavior in HIV Positive Female Adolescents
PTSD and Risk Behavior in HIV Positive Female Adolescents
Status: Enrolling
Updated:  2/27/2017
Montefiore Medical Center
mi
from
Bronx, NY
PTSD and Risk Behavior in HIV Positive Female Adolescents
PTSD and Risk Behavior in HIV Positive Female Adolescents
Status: Enrolling
Updated: 2/27/2017
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
PTSD and Risk Behavior in HIV Positive Female Adolescents
PTSD and Risk Behavior in HIV Positive Female Adolescents
Status: Enrolling
Updated:  2/27/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
PTSD and Risk Behavior in HIV Positive Female Adolescents
PTSD and Risk Behavior in HIV Positive Female Adolescents
Status: Enrolling
Updated: 2/27/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated:  2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated: 2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated:  2/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated: 2/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated:  2/27/2017
Children's Hospital National Medical Center
mi
from
Washington,
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated: 2/27/2017
Children's Hospital National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated:  2/27/2017
University of South Florida
mi
from
Tampa, FL
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated: 2/27/2017
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated:  2/27/2017
Stroger Hospital of Cook County
mi
from
Chicago, IL
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated: 2/27/2017
Stroger Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated:  2/27/2017
University of Maryland
mi
from
Baltimore, MD
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated: 2/27/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated:  2/27/2017
Mount Sinai Hospital
mi
from
New York, NY
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated: 2/27/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated:  2/27/2017
University Pediatric Hospital
mi
from
San Juan,
C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions
Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation
Status: Enrolling
Updated: 2/27/2017
University Pediatric Hospital
mi
from
San Juan,
Click here to add this to my saved trials
Life Skills Intervention for Adolescents Perinatally Infected With HIV
Life Skills Intervention for Young Adolescents Perinatally Infected With HIV and Their Caregivers
Status: Enrolling
Updated:  2/27/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Life Skills Intervention for Adolescents Perinatally Infected With HIV
Life Skills Intervention for Young Adolescents Perinatally Infected With HIV and Their Caregivers
Status: Enrolling
Updated: 2/27/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated:  2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated: 2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated:  2/27/2017
University of California, San Diego
mi
from
San Diego, CA
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated: 2/27/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated:  2/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated: 2/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated:  2/27/2017
Childrens National Medical Center
mi
from
Washington,
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated: 2/27/2017
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated:  2/27/2017
Children'S Diagnostic Treatment Center
mi
from
Fort Lauderdale, FL
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated: 2/27/2017
Children'S Diagnostic Treatment Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated:  2/27/2017
University of Miami
mi
from
Miami, FL
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated: 2/27/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated:  2/27/2017
Stroger Hospital of Cook County
mi
from
Chicago, IL
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection
Status: Enrolling
Updated: 2/27/2017
Stroger Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials